Program
zetrukibart
In Sanofi's pipeline, IL1R3 mAb
. Its studies are mostly in Hidradenitis Suppurativa · Bronchiectasis, led by Sanofi.
Furthest: phase 2, since Nov 4, 20252 company-led studies, 1 open or runningNext primary completion: Sep 22, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 21 open or running | phase 2since Nov 4, 2025 | Nov 4, 2025 | Sep 22, 2027phase 2 · NCT07225569 |
- Named in Sanofi’s own pipeline as
SAR445399
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2025First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT07225569 · 144 planned · United States, Argentina, Australia and more
- Apr 17, 2026Phase 2 study in BronchiectasisNCT07547436 · 70 enrolled · United States
Ahead
- Sep 22, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07225569
TargetBeta
“IL1R3 mAb”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07547436Bronchiectasis · United States | 2 | Suspended | Oct 29, 2027 | 70 |
| NCT07225569Hidradenitis Suppurativa · United States, Argentina, Australia and more | 2 | Recruiting | Sep 22, 2027 | 144 |
How it is read
Names in the registry
- “SAR445399”, 2 entries
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.